Skip to content
★ Sign in to follow
바이

바이오인프라 Stock: price and insider trades · South Korea

KR·Mcap ₩7.9BHealth Care

No insider purchase over the last 90 days. The latest, by 이영국, was filed 08 Jun 2026.

바이오인프라: what insiders have been doing

바이오인프라, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). In the past year (28 October 2025 to 28 October 2026), 1 filing came from 1 insider.

The flow runs one way only: 1 insider bought (1 purchase) and nobody sold on the market. The totals do not cover 1 filing with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 senior executive.

The most recent open-market purchase was published on 8 June 2026, 153 days ago.

For context, the typical company on the same exchange (median of 2,654 companies) published 7 filings over the same period, against 1 filing here. Looking back to 2023, when coverage begins, insiders filed 5 purchases and 7 sales.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.

Insider Decl.
12
Thresholds
n/a
Buy Volume
€5,409
5 ops. · all time
Sell Volume
€7M
7 ops. · all time

Who traded when

BuySale
김장현1 sale
안형준1 buy
이영국1 buy
Fundamental score
Ranked 26,499 of 26,914 companies
8.5
score / 100
Value
2
Quality
15
FCF yld-55%
Earn yld-165%
EV/EBITDA·
ROE-48%
Gross mgn23%
Net mgn-39%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩1,634
Analyst consensus
·
Income statement
Revenue₩23.1B
Gross profit₩5.3B23% margin
EBITDA-₩4.3B-19% margin
Net income-₩9.1B-32.3% margin
Valuation
Beta0.52
Balance sheet & cash
Market cap₩7.9B
Total debt₩11.9B
Free Cash Flow-₩3B
Debt / Equity109%
Profitability & ownership
ROE-47.5%
ROA-9.1%
% insiders42.4%
% institutions0.0%
Last declaration on 8 June 2026
Declarations13 total
  • Other
    Other(filed)
    0DART
  • ▲
    전무Executives(filed)
    €4,853est.0DART
    3,000 sharesShareKRXDART:20260608000176
    Canonical exit: 6 Sept 2026 (T+90)
  • ▼
    대량보유자Executives
    €223kest.0DART
    58,996 sharesKRXDART:20250605000366
  • ▲
    사외이사Executives(filed)
    €557est.0DART
    120 sharesShareKRXDART:20241203000387
    Canonical exit: 3 Mar 2025 (T+90)
  • ▲
    상무Executives
    0DART
    ShareKRXDART:20240613000053
    Canonical exit: 1 Aug 2024 (T+90)
  • ▲
    상무Executives
    0DART
    ShareKRXDART:20240507000088
    Canonical exit: 1 Aug 2024 (T+90)
  • ▼
    Executives
    €951kest.0DART
    58,996 sharesKRXDART:20230428001669
  • ▼
    Executives(filed)
    €1.0Mest.0DART
    58,996 sharesKRXDART:20230404000653
  • ▼
    Executives(filed)
    €1.0Mest.0DART
    58,996 sharesKRXDART:20230403004587
  • ▼
    Executives(filed)
    €1.0Mest.0DART
    58,996 sharesKRXDART:20230309000223
  • ▼
    Executives(filed)
    €1.0Mest.0DART
    58,996 sharesKRXDART:20230309000857
  • ▲
    상무Executives(filed)
    0DART
    ShareKRXDART:20230309000741
    Canonical exit: 7 Jun 2023 (T+90)
  • ▼
    Executives(filed)
    €1.2Mest.0DART
    58,996 sharesKRXDART:20230306000495

13 of 13 declarations

About 바이오인프라

BioInfra is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions to enhance human health.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations